(Date:12/16/2009)... -- Capitalizing on the continued strong growth ... venture capital market, leaders from BioCrossroads, Eli Lilly ... University, Purdue University, the University of Notre Dame, ... announced the establishment of the INext Fund, a ... Organized through BioCrossroads, Indiana,s initiative to grow, expand ...
(Date:12/16/2009)... Special Protocol Assessment with the Food and ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on oncology and ... its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( ... trial for perifosine (KRX-0401), the Company,s PI3K/Akt ...
(Date:12/16/2009)... its 23rd Annual Technical Conference & Exhibition on March 22-25, 2010 ... impact the separation society and reach out to even more experts ... AFS Annual Technical Conference will be co-located with the 2010 AIChE ... ... December 16, 2009 -- The American Filtration and Separations Society will ...
(Date:12/15/2009)... Dec. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... of China ("PRC"), today,announced that the Company has ... 2009,Edition of the National Basic Medical Insurance, Industrial ... The 30 medicines treat a ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5American Filtration and Separations Society to Hold 23nd Annual Technical Conference 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 3American Filtration and Separations Society to Hold 23nd Annual Technical Conference 4China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3... LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June ... AB (Nordic Exchange: BINV) announce that they have,entered ... for their jointly,developed anti-cancer agent TB-403. TB-403 is ... (PIGF), one of the growth factors,responsible for the ...
... Top 40, EAST HARTFORD, Conn., June 17 ... a new awards program in,partnership with accounting firm UHY ... companies in Connecticut. Companies will be,recognized on the basis ... revenue requirement of $50,000 and minimum revenues of $3 ...
... (Nasdaq: CADX ), a biopharmaceutical company focused ... use in the hospital setting, announced today that ... the corporate overview on,Monday, June 23, 2008 at ... Swann Pain Roundtable Conference at the Sofitel Hotel ...
Other Biology Technology:ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody 2ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody 3ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody 4ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody 5ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody 6Connecticut Technology Council to Recognize Fast Growing Technology Companies 2Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York 2(Date:12/15/2009)... German ., Despite the fact that physical ... vary as to how space is encoded in their ... such as ,left, right, front, back, to talk about ... east, west, at all times for all scales: "The ... an snake by your Northern leg". Whether not only ...
(Date:12/15/2009)... an enormous emotional and economic toll on society. It ... currents each year in U.S. waters and it,s likely that ... A serious disconnect exists between rip current research and ... tides and undertows, and more importantly, most people do not ... rip current. , The goal of the Rip Current Symposium ...
(Date:12/14/2009)... 14, 2009) -- Researchers at Rice University and Baylor ... that can be tracked in real time with MRI ... with a fluorescent dye and kills them with heat. ... from a growing field called "theranostics" that develops technologies ... a single procedure. , The research is available online ...
Breaking Biology News(10 mins):More than a jump to the left 2Tracking new cancer-killing particles with MRI 2Photos 3A First of Its Kind Website Unveiled at Modern Moms Meet Modern Science Meeting 59728 1Photos 3A First of Its Kind Website Unveiled at Modern Moms Meet Modern Science Meeting 59728 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 1AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin 28AEZS 130 29 as First Oral Diagnostic Test for Growth Hormone Deficiency 14520 3Talecris Biotherapeutics Receives FDA Approval for PROLASTIN 28R 29 C 5548 1Talecris Biotherapeutics Receives FDA Approval for PROLASTIN 28R 29 C 5548 2Talecris Biotherapeutics Receives FDA Approval for PROLASTIN 28R 29 C 5548 3Talecris Biotherapeutics Receives FDA Approval for PROLASTIN 28R 29 C 5548 4Talecris Biotherapeutics Receives FDA Approval for PROLASTIN 28R 29 C 5548 5General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... for fully automated systems for a broad ... configured for applications ranging from compound logistics, ... loop screening, which means it has fully ... picking and follow up studies all at ...
... over 20 years of experience in providing ... Sciences, the Freedom EVO platform delivers even ... to future needs. Together with the new ... equipped to successfully operate genomics, proteomics, and ...
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
Biology Products:Biology NavigationMedical Navigation